Trials / Completed
CompletedNCT01244828
Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)
Long-term Study of Asenapine in Subjects With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (Protocol P06238)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 157 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-site, open-label fixed-flexible dose long-term study of asenapine in participants with schizophrenia. Participants in this study consist of schizophrenia with residual subtype or receiving high dose/multiple antipsychotic drugs, treatment refractory, or elderly participants with schizophrenia. The treatment period is up to 52 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Asenapine | 5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks |
Timeline
- Start date
- 2011-04-05
- Primary completion
- 2014-08-21
- Completion
- 2014-08-21
- First posted
- 2010-11-19
- Last updated
- 2024-05-28
- Results posted
- 2015-08-26
Source: ClinicalTrials.gov record NCT01244828. Inclusion in this directory is not an endorsement.